Recombinant NKG2A (Monalizumab Biosimilar) 抗体
This anti-NKG2A (Monalizumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting NKG2A (Monalizumab Biosimilar) in ELISA 和 WB. Suitable for 人.
Quick Overview for Recombinant NKG2A (Monalizumab Biosimilar) 抗体 (ABIN7538069)
抗原
NKG2A (Monalizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated
应用范围
ELISA, Western Blotting (WB)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
-
产品特性
- Antibody Type: IgG4-kappa
-
纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
-
纯度
- > 85%
-
亚型
- IgG4
-
-
-
-
限制
- 仅限研究用
-
-
-
缓冲液
- PBS buffer PH7.5
-
储存条件
- -80 °C
-
储存方法
- store at -80°C
-
-
- NKG2A (Monalizumab Biosimilar)
-
背景
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
-
CAS-编号
- 1228763-95-8
抗原
-
You are here:
